ARTICLE | Clinical News
Merrimack discontinues last clinical candidate
April 12, 2019 7:13 PM UTC
Merrimack discontinued development of MM-310 -- the company's last remaining product in clinical testing -- after a safety update showed that a Phase I trial in solid tumor patients "would not be able to reach an optimal therapeutic index for MM-310" due to continued observation of cumulative peripheral neuropathy.
Last year, Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) discontinued development of Phase II cancer therapies istiratumab (MM-141) and seribantumab (MM-121)...
BCIQ Company Profiles
BCIQ Target Profiles